In Vitro Fertilization (IVF)
IVF can be a powerful treatment, but it is not a black box and it is not without limits. A central part of Dr. Cameron's role is helping patients understand what IVF is actually doing, what the process involves, and how individual factors shape the likelihood of success.
At the start of each month, the ovaries identify a group of eggs that could potentially grow. Outside of fertility treatment, the body typically produces only enough hormone to mature one of them, while the rest of that group naturally falls away — one of the inefficiencies of our reproductive biology. In IVF, medication provides extra hormone so that more of that month's available group can grow at once. How many respond depends largely on a patient's own egg supply, which is why two people can respond very differently to the same protocol.
The process takes about two to three weeks of daily hormone injections and frequent monitoring — ultrasounds and bloodwork every few days — so the ovaries' response can be tracked closely. Once they're ready, a final trigger injection is given, followed roughly 34 to 36 hours later by a short egg retrieval under anesthesia.
When counseling patients about success, Dr. Cameron focuses on two variables: egg supply (how many eggs a cycle may yield) and egg quality (the likelihood an egg can create a chromosomally normal embryo). Age matters significantly here, especially from around 35, when the proportion of good-quality eggs begins to decline.
She also helps patients think deliberately through embryology decisions — conventional insemination versus ICSI, and whether preimplantation genetic testing adds meaningful value — using the right tools in the right clinical context rather than applying every available technology by default. And before beginning, she emphasizes honest expectation-setting: whether one cycle is likely to be enough, or whether several may be needed for that individual.
Fertility Preservation & Oncofertility
Fertility preservation is one of Dr. Cameron's distinctive areas of expertise — counseling people facing a new cancer diagnosis, those preparing for medical treatment that may affect fertility, and survivors looking ahead to building a family after treatment.
The most important shift in how this care is delivered is that the conversation is no longer a single moment before treatment — it's a continuum. The 2025 ASCO guideline update formally recognized this, recommending fertility discussions not only at diagnosis and before therapy, but throughout survivorship as well. That matters because a great deal can change: a treatment plan may shift, and a patient — understandably overwhelmed at diagnosis — may only be ready to think about family-building once treatment is behind them. Dr. Cameron meets patients at whichever point they arrive.
Before treatment, timing can be urgent, sometimes a matter of days. The mainstay of fertility preservation is mature egg freezing, which has the strongest real-world outcome data and fully preserves a patient's future autonomy. Embryo freezing is an option for those with a partner they're certain about, though it raises future-disposition questions worth thinking through. For patients who can't wait the two to three weeks egg freezing requires, or who haven't reached puberty, ovarian tissue freezing may be part of the discussion, and newer approaches such as in vitro maturation are on the horizon.
In survivorship, Dr. Cameron helps patients understand how treatment may have affected their fertility, what their remaining options are, and — importantly — that the window for some interventions can be narrower after treatment, so the timing of that conversation matters.
Throughout, she works in close coordination with oncology teams, because fertility decisions for these patients can't be made in isolation from the cancer care itself. Her aim is for every patient to understand their options, how quickly decisions need to be made, and what outcomes may realistically look like — without false reassurance, and without anything left unsaid.
Su et al., ASCO Fertility Preservation Guideline Update, J Clin Oncol 2025 —https://pubmed.ncbi.nlm.nih.gov/40106739
Recurrent Pregnancy Loss
Recurrent pregnancy loss is medically complex and emotionally exhausting, and Dr. Cameron approaches it with careful evaluation, honest counseling, and real sensitivity to the fact that many patients bring fear — not joy — into the next pregnancy after loss.
Evaluation is generally recommended after two or more losses; there is no need to wait for a third. By far the most common cause of early loss is a chromosomal abnormality in the embryo — random, and common enough that a loss, or even two, does not necessarily signal an underlying problem.
The most meaningful recent change in how recurrent loss is evaluated is that, when possible, the workup now begins by testing the genetic makeup of the miscarriage tissue itself. This single step helps triage everything else: if the tissue shows a chromosomal abnormality, that often explains the loss and can spare a patient an extensive evaluation; if it is chromosomally normal, that is the signal to look further. Combined with the standard workup — a careful assessment of the uterine cavity, testing for antiphospholipid syndrome, thyroid and other relevant bloodwork, and parental chromosome testing in selected cases — this approach now identifies a likely explanation in the large majority of patients, where previously more than half were left without one. [2]
When no cause is found — now a smaller group than in the past — Dr. Cameron focuses on what that does and does not mean. Most of these patients still have a meaningful chance of future success. IVF with preimplantation genetic testing may be appropriate in select situations, particularly for someone who feels they cannot move forward without doing everything possible to lower the risk of another chromosomally abnormal pregnancy, but it is not automatically the right answer for everyone. Her counseling is intentionally non-directive: she lays out the data, talks through the possible paths, and helps each patient choose the one that fits their goals and emotional readiness.
ASRM Recurrent Pregnancy Loss committee opinion, 2026 - https://pubmed.ncbi.nlm.nih.gov/42062119/]
Polyendocrine Metabolic Ovarian Syndrome (PMOS), formerly PCOS
Polyendocrine metabolic ovarian syndrome — the condition long known as polycystic ovary syndrome, or PCOS — is one of the most common and most misunderstood conditions Dr. Cameron treats. The 2026 renaming reflects something she emphasizes with every patient: this is not simply an ovarian or reproductive problem, but a whole-body endocrine and metabolic condition. The old name was misleading, because the "cysts" seen on ultrasound are not true cysts at all — they are small, immature follicles.
In plain terms, Dr. Cameron explains PMOS as an interruption in the normal communication between the brain and the ovaries, driven in part by elevated androgen hormone levels. When that communication is disrupted, ovulation may not happen regularly, and periods become unpredictable or absent. Diagnosis rests on two of three features — irregular ovulation, signs of elevated androgens (by exam or bloodwork), and the characteristic ovarian appearance on ultrasound — after ruling out the rarer conditions that can mimic it.
Because PMOS is metabolic as well as reproductive, Dr. Cameron counsels patients on its longer-term health dimensions, not just fertility — including its links to insulin resistance, diabetes, cardiovascular risk, and, when ovulation is absent over many years, cancer of the lining of the uterus. That broader view matters even for patients who are not trying to conceive.
For those who are, there is genuine reassurance: patients with PMOS often need the least intensive fertility treatment to succeed. First-line oral medication to restore ovulation is often enough for many people to conceive, and when it’s not, patients with PMOS often respond very well to IVF. One last point Dr. Cameron makes often: the common advice to "try for a year before seeing a specialist" applies only to people with regular cycles. If you have PMOS and aren't ovulating predictably, you aren't getting those monthly chances — and you shouldn't wait.
https://pubmed.ncbi.nlm.nih.gov/42119588/
2023 International Evidence-Based Guideline for PCOS — https://pubmed.ncbi.nlm.nih.gov/37580861/
Fertility Care for People with Complex Medical Conditions
Some patients arrive with a fertility question layered on top of a serious or complicated medical picture — a cancer diagnosis, a blood disorder such as sickle cell disease or thalassemia, an autoimmune condition, a heritable genetic condition, or a treatment plan that itself carries reproductive risk. These are the cases that many high-volume clinics find difficult, and they are exactly the cases Dr. Cameron is drawn to.
Two things make this care different. The first is that the evidence is often thinner and the choices harder. There is rarely a clean, one-size answer, and there are often tradeoffs between a patient's fertility goals and their broader health. Dr. Cameron's training in clinical epidemiology and bioethics is most useful precisely here — appraising what the data do and don't support, and helping patients work through decisions where more than one path may be reasonable, starting from their own values.
The second is that this care cannot happen in a silo. Dr. Cameron champions a multidisciplinary approach, coordinating closely with a patient's team which may include oncologist, hematologist, maternal-fetal medicine specialist, geneticist, or other physicians, so that reproductive decisions are made in the full context of someone's health rather than apart from it.
LGBTQ+ Family Building
Building a family looks different for different people, and Dr. Cameron provides knowledgeable, affirming care across the full range of paths — for same-sex couples, transgender and gender-diverse individuals, and single parents by choice.
Third-party reproduction is a particular area of her expertise: care that involves donor sperm, donor eggs, donor embryo, or a gestational carrier. Depending on a family's goals, that may mean intrauterine insemination with donor sperm, IVF using donor eggs or donor sperm, reciprocal IVF — in which one partner provides the eggs and the other carries the pregnancy — or building a family with the help of a gestational carrier. For transgender and gender-diverse patients, it may also mean fertility preservation before gender-affirming treatment. Dr. Cameron helps each individual and couple understand the options realistically and choose the path that fits their circumstances.
This is also an area where careful, values-based counseling matters as much as the medicine. Third-party reproduction raises genuinely meaningful questions — about known (directed) versus anonymous (non-identified) donors, future disclosure to children, what each person’s role will be, and the interests of everyone involved, including future children. Dr. Cameron's background in bioethics directly shapes how she navigates these conversations: laying out the considerations honestly, respecting that reasonable people weigh them differently, and helping patients make decisions they can stand behind. Her aim is for every person who comes to her to feel respected, fully informed, and genuinely supported in building their family their way.